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Abstract
Background: Modification of ritonavir-boosted lopinavir (LPV/r)-based antiretroviral therapy is required for HIV-infected
children co-treated for tuberculosis (TB). We aimed to determine virologic and toxicity outcomes among TB/HIV co-treated
children with the following modifications to their antiretroviral therapy (ART): (1) super-boosted LPV/r, (2) double-dose LPV/r
or (3) ritonavir.
Methods and Findings: A medical record review was conducted at two clinical sites in Johannesburg, South Africa. The
records of children 6–24 months of age initiating LPV/r-based therapy were reviewed. Children co-treated for TB were
categorized based on the modifications made to their ART regimen and were compared to children of the same age at each
site not treated for TB. Included are 526 children, 294 (56%) co-treated for TB. All co-treated children had more severe HIV
disease, including lower CD4 percents and worse growth indicators, than comparisons. Children in the super-boosted group
(n=156) were as likely to be virally suppressed (,400 copies/ml) at 6 months as comparisons (69.2% vs. 74.8%, p=0.36).
Children in the double-dose (n=47) and ritonavir groups (n=91) were significantly less likely to be virally suppressed at 6
months (53.1% and 49.3%) than comparisons (74.8% and 82.1%; p=0.02 and p,0.0001, respectively). At 12 months only
children in the ritonavir group still had lower rates of virological suppression relative to comparisons (63.9% vs 83.3%
p,0.05). Grade 1 or greater ALT elevations were more common in the super-boosted (75%) than double-dose (54.6%) or
ritonavir (33.9%) groups (p=0.09 and p,0.0001) but grade 3/4 elevations were observed in 3 (13.6%) of the super-boosted,
7 (15.9%) of the double-dose and 5 (8.9%) of the ritonavir group (p=0.81 and p=0.29).
Conclusion: Good short-term virologic outcomes were achieved in children co-treated for TB and HIV who received super-
boosted LPV/r. Treatment limiting toxicity was rare. Strategies for increased dosing of LPV/r with TB treatment warrant
further investigation.
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Introduction
An increasing proportion of the global burden of tuberculosis
(TB) is related to HIV, with the highest rate of dual infection
occurring in Sub-Saharan Africa.[1] In 2008, 9.4 million new TB
caseswerediagnosed globally ofwhich30%occurred inthe African
region.[2] Children make up approximately 10% of the TB
burden.[3] One of a few African studies estimates the incidence of
TB in HIV-infected children to be 1,600 per 100,000 increasing
further in severely immunocompromised children or children
with high viral load.[4] Compared with HIV-uninfected children
with TB, HIV-infected children with TB and not receiving
antiretroviral therapy (ART) have a six times greater risk of
dying.[5]
Both TB and HIV require multiple drugs for effective treatment
and the situation is complicated by drug interactions between
antiretrovirals and rifampicin, the most commonly used drug for
TB treatment. Rifampicin is a strong inducer of cytochrome p450
enzymes, particularly CYP3A isoenzymes and p-glycoprotein,
[6,7] resulting in accelerated clearance of protease inhibitors
(PI).[8,9,10,11] Ritonavir is a strong inhibitor of CYP3A.[12]
Most PI’s are boosted with low dose ritonavir to ensure sustained
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that the mininmum serum concentration (Cmin) of indinavir,
lopinavir and atazanavir were decreased by .90% when given
with the standard ritonavir-boosting dose of 100 mg in the
presence of rifampicin.[8,9,10]
PI-based therapy using ritonavir-boosted lopinavir (LPV/r) is
the recommended first-line regimen for HIV-infected infants and
young children ,3 years of age in South Africa,[13] and WHO
recommends that infants failing nevirapine-containing prophylaxis
should be started on a PI containing regimen.[14]
A pediatric study confirmed that trough concentrations of
lopinavir with rifampicin were best preserved by adding extra
ritonavir to give a LPV/r: Ritonavir ratio of 1:1 referred to as
‘‘super-boosted’’ LPV/r.[15] However, while in the pediatric
study, there were no treatment interruptions for liver enzyme
elevations [15], super-boosted dosing has been associated with
hepatotoxicity in adults.[10] A simpler approach would be to
increase the LPV/r dose, although double-dosing LPV/r in HIV-
infected children receiving rifampicin did not result in the
achievement of therapeutic levels of lopinavir.[11] Combined
use of lopinavir, ritonavir and rifampicin is challenging requiring
evaluation of efficacy and toxicity.[16]
Here we evaluate, in the context of two large pediatric HIV
treatment programs in Johannesburg, South Africa, the toxicity
and therapeutic outcomes of ritonavir or adjusted dose regimens of
LPV/r in combination with rifampicin-based TB treatment
among HIV-infected children initiating ART between the ages
of 6 months and 2 years.
Methods
Study sites
We conducted a retrospective record review at two clinical sites
providing pediatric HIV treatment in Johannesburg, South Africa:
the Harriet Shezi Children’s Clinic (Shezi) at Chris Hani
Baragwanath Hospital and the Neverest research site at Rahima
Moosa Mother and Child Hospital. At both sites, infants and
young children under the age of 2 years were initiated onto first-
line therapy with LPV/r, lamivudine and stavudine. Children
receiving TB treatment were compared to children of the same
age receiving ART but no TB treatment, and co-treated children
were further stratified by the modifications made to their PI.
Virologic and toxicity outcomes within the first 6 to 12 months
after ART and TB treatment in TB cases and ART initiation in
the comparison group were investigated.
Participants
The study population included all HIV-infected children 6–24
months of age who initiated ART between April 2004 and May
2007. The Shezi clinic provides HIV care for approximately 3 500
HIV-infected children. LPV/r, stavudine and lamivudine is the
routine first-line regimen for children ,3 years of age and
clinically-stable children are followed at 3-monthly intervals. Viral
loads, CD4 counts and liver function tests are conducted 6
monthly. The Neverest Study was a treatment strategies trial in
which children who had prior exposure to NVP prophylaxis and
subsequently required ART, were treated with LPV/r, stavudine
and lamivudine. Enrollment started in April 2005. Once
confirmed viral suppression occurred, children were randomized
to continue LPV/r-based therapy or to start NVP-containing
treatment. Viral loads and CD4 counts were conducted pre-
treatment and three monthly thereafter. Doses were calculated
based on body surface area calculations or weight and were
modified at each visit.
At the time of the study, South African guidelines recommended
ritonavir-based ART with TB treatment and this was adhered to
for most of the Neverest study.[17] At Harriet Shezi Clinic it was
the clinicians’ decision to use adjusted doses of LPV/r. Initially
super-boosted LPV/r was used, but double dosing of LPV/r was
also used for some children because this was simpler for caregivers
and children and adult data suggested feasibility of these
approaches.[10]
TB or BCG disease treatment
Treatment recommendations of pulmonary TB in children
include rifampicin, isoniazid and pyrazinamide in the induction
phase (2 months) and rifampicin and isoniazid in the continuation
phase (4 months).[18] Extrapulmonary TB requires the addition of
ethionamide or ethambutol in the induction phase and a longer
course of treatment. BCG adenitis and BCG disease are treated
with rifampicin, isoniazid and ethionamide or ethambutol for at
least 6 months tailored to clinical response. Mycobacterium bovis
is universally resistant to pyrazinamide. [13]
Definition of the groups
Children were divided into those co-treated for TB (TB-treated)
and those not treated for TB but who received LPV/r-containing
ART (comparisons). If children were counted as TB-treated, their
periods free of TB treatment were not included in the comparison
cohort. Time0 in the TB-treated referred to the earliest time both
rifampin-based treatment and ART were concomitantly received,
irrespective of which was initiated first. Time0 in comparisons was
the time of initiation of antiretroviral treatment. Given the high
frequency of TB treatment in these cohorts, all children not
receiving TB treatment were included as comparisons.
The basis on which the decision to initiate rifampicin-based TB
treatment was extracted from the records. Clinical suspicion
included any of the following; TB contact, cough of .2 weeks
duration, failure to thrive and/or suggestive radiological findings.
Definitive diagnosis included either a positive tuberculin skin test
($5 mm induration),[17] a positive smear for acid fast bacilli or a
positive culture for Mycobacterium tuberculosis or Mycobacterium bovis.
TB-treated children were subdivided into three groups accord-
ing to the formulation of the PI that was received whilst receiving
TB treatment namely:
1. Super-boosted LPV/r - 230 mg/m
2 Lopinavir and ritonavir
57.5 mg/m
2 with additional ritonavir 172.5 mg/m
2
2. Double-dose LPV/r - 460–600 mg/m
2
3. Ritonavir only - 460–600 mg/m
2
Children who changed categories while being treated for TB were
included in the category they spent the most time.
Children were excluded from the study if they had chronic liver
disease, Mycobacterium Avium Complex infection or metabolic disease.
They were also excluded if they received an initial regimen which
included drugs other than LPV/r, ritonavir, stavudine and
lamivudine, or if their paper record could not be found.
Participants were considered lost to follow up if there was no 12
month visit and they were not known to have died by that point.
Antiretroviral treatment outcomes
Toxicity was assessed by alanine aminotransferase (ALT) and
hemoglobin measurement and whether or not treatment was
interrupted. ALT and hemoglobin values were classified into their
toxicity grade using normal values for this population from the
local laboratory and Division of AIDS, National Institute of
Health (DAIDS) grading tables.[19] ART outcomes included viral
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tification range 400–750,000 copies/ml, Roche Amplicor,
Branchburg, NJ), CD4 response and changes in weight-for-age
and height-for-age. Weight-for- age Z-scores (WAZ) and height-
for-age Z-scores (HAZ) were calculated using WHO software.[20]
Anthropometric measurements and laboratory data were extract-
ed from the patients’ files and the clinic databases.
Ethics
The Neverest study was approved by the institutional review
board of Columbia University and the Human Sciences Research
Ethics Committee (HSREC) of the University of the Witwaters-
rand. Approval to review hospital record retrospectively at Harriet
Shezi Children’s Clinic was obtained from the HSREC of the
University of the Witwatersrand. Informed consent was required
for children participating in the Neverest study, although at
Harriet Shezi, informed consent to store patient information in the
data base was not obtained since this was originally conceived for
primary care purposes.
Statistical analysis
Clinical characteristics of the children pre-ART and within 6
and 12 months of time0 were compared between groups. TB-
treated children receiving super-boosted and double-dose LPV/r
at Shezi and TB-treated children on ritonavir from Neverest were
compared to nonTB-treated children receiving LPV/r therapy at
each site respectively (comparison groups). Wilcoxon tests were
used to compare continuous and Chi-square test or Fisher’s exact
test for categorical variables. To consider whether pre-treatment
differences between the groups explained differences in viral
suppression rates, multivariable logistic regression models were
conducted. Factors significantly associated with the outcome
(p,0.05) or which once included modified the association between
treatment group by .10% were included in final models.
Results
Study population
Between the two sites, 526 children 6–24 months were initiated
onto a LPV/r-based regimen and 294 (56%) were co-treated for
TB (figure 1). Of these, 156 (53.1%) received super- boosted LPV/
r, 47 (16.0%) double-dose LPV/r and 91 (31.0%) ritonavir-based
regimens. ART was started after TB treatment in 78.2% of TB-
treated and before TB treatment in 21.8%. Amongst these, the
median time between ART and TB treatment initiation was 54
days (IQR: 32-93) and did not differ between the three groups
(Table 1). In children who started TB treatment after ART, the
median time from ART start until TB treatment start was 42 days
(IQR: 21.5-84). Most of the children (76.5%) who initiated TB
treatment had a diagnosis of pulmonary TB and 8.4% of these
were additionally diagnosed with BCG disease. Eight children
(2.7%) were diagnosed with extra-pulmonary TB disease (2
Figure 1. Flow diagram of study participants.
doi:10.1371/journal.pone.0017273.g001
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further 30 children received TB treatment only for BCG disease
(Table 1). Children diagnosed with pulmonary TB were older
(median age in months at ART start: 13 IQR: 10-17) than children
diagnosed with BCG alone (median age of 7 months (IQR: 7-10);
p,0.0001). TB was confirmed on microbiological grounds in
17.2% and PPD in 7.4%. Clinical suspicion for TB was the basis
for diagnosis in 75.4% of children.
Pre-ART characteristics
TB-treated children had significantly lower pre-ART CD4
percents and lower HAZ and WAZ than comparisons (Table 2).
Severity of disease differed across the sites with more severe disease
at the Shezi site. Pre-ART viral load, ALT and hemoglobin did
not differ between the three co-treatment groups and their
comparisons (Table 2). The median age at ART start in children
co-treated for TB prior to initiating ART was 13.2 months (IQR:
9.7-17) compared to a median age of 9.2 months (IQR: 6.9-15.6
months) in co-treated children who started TB treatment after
ART (p,0.0001).
Mortality and loss to follow-up
In the 12 months after time0, 46 (8.9%) children died. This
includes 17/232 (7.3%) comparisons, 21/230 (9.1%) co-treated for
TB at time of ART initiation and 8/64 (12.5%) who initiated TB
treatment after ART, there were no significant differences in
mortality between the TB-treated and comparison groups. In the
super-boosted LPV/r group 17 (10.9%) died, in the double-dose,
one child (2.1%), and in the Ritonavir group, 11 children (12.1%)
died. Children who died were significantly younger (median age at
ART initiation 10 months (IQR: 7-15) than children who survived
(median age 13 months, IQR: 9-18, p=0.0008). Children who
died had lower mean WAZ, higher pre-treatment viral loads and
lower CD4 percentages (data not shown).
Table 1. Characteristics of children who initiated TB treatment by modification made to antiretroviral treatment (ART) regimen.
Total Super-boosted LPV/r Double-dose LPV/r Ritonavir p-value
TB-treated 294(100) 156(100) 47(100) 91(100)
Confirmed TB 72(24.6) 41(26.3) 12(25.5) 19(20.9)
Clinical suspicion for TB 222(75.4) 115(73.7) 35(74.5) 72(79.1) 0.63
TB therapy at ART start 230 (77.6) 128 (82.1) 37 (78.7) 65 (71.4) 0.15
Median days (IQR) from
TB therapy to ART start
54 (32–93) 56 (28–94) 46 (22–74) 55 (43–93) 0.18
Median days (IQR) ART
start to TB therapy start
42 (21–84) 42 (29–80) 37(21–252) 41 (18–75) 0.89
Type of TB diagnosis*
Pulmonary TB 225 (76.5) 128 (82.1) 35 (74.5) 62 (68.1) 0.04
Extra-pulmonary TB 8 (2.7) 5 (3.3) 1 (2.2) 2 (2.2) 0.86
BCG disease 49 (16.7) 27 (17.3) 7 (14.9) 15 (16.5) 0.93
Unknown 31 (10.5) 8 (5.1) 9 (19.1) 14 (15.4) 0.004
Diagnostic evaluations*
Pulmonary TB
Radiological-suspected 146 (64.9) 95 (74.2) 24 (68.6) 27 (43.6) 0.0002
Positive culture or smear 38 (16.9) 28 (21.9) 5 (13.9) 5 (8.2) 0.23
PPD positive 16 (7.1) 8 (6.3) 2 (5.7) 6 (9.8) 0.18
Other diagnostic test** 3 (1.3) 2 (1.6) 1 (2.9) 0 (0) 0.39
Extra-pulmonary TB
Positive culture or smear 2(25) 2(40) 0(0) 0(0) 0.45
PPD positive 1(10) 0(0) 1(50) 0(0) 0.02
BCG disease
Positive culture or smear 13(26.5) 6(22.2) 2(28.6) 5(33.3) 0.14
PPD positive 1(2.0) 0(0) 0(0) 1(6.7) 0.08
Median days (IQR)
duration of TB therapy
All TB-treated 203 (181–261) 200 (178–254) 198 (184–244) 208 (184–265) 0.30
Pulmonary TB 200 (178–238) 195 (176–236) 198 (175–221) 204 (182–258) 0.30
Extra-pulmonary TB 245 (195–263) 212 (180–245) 229 (195–263) 321 (279–363) 0.10
BCG disease 212 (184–271) 236 (183–299) 195 (192–205) 206 (196–253) 0.56
Other medications*** 9 (3.1) 6 (3.9) 1(2.1) 2 (2.2) 0.71
*Percents add up to .100% because more than one type of TB or diagnostic intervention was possible in the same child.
**Other diagnostic evaluations include lymph node biopsy (2), gastric washing (1).
***Other medications include prednisone (3), ciprobay (3), ethambutol (3).
doi:10.1371/journal.pone.0017273.t001
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to follow-up and another 22 children (4.2%) were transferred to
other services and did not have 12 months data available. There
were no significant differences between the groups in rates of loss
to follow-up.
Toxicity and treatment interruptions in co-treated
children
Among the children assessed for liver function, ALT elevations
$grade 1 were more common in the super-boosted group (75%)
than in the double-dose (54.6%) or ritonavir (33.9%) groups
(p=0.09 and p,0.0001) but differences did not reach significance
if only elevations greater than grade 2 were considered (Table 3).
Seventeen children (5.8%) had an ART interruption while co-
treated for TB: 6 (3.9%) in the super-boosted, 3 (6.4%) in the
double-dose and 8 (8.8%) in the Ritonavir group (p=0.24). One
child in the super-boosted group and 3 children in the ritonavir
group interrupted treatment because of an elevated ALT and one
in the ritonavir group due to neutropenia. Among the compar-
isons, 5 (3.9%) at the Shezi site and 7 (6.7%) at the Neverest site
interrupted ART. One of the interruptions among the compar-
isons was due to hepatotoxicity with an ALT grade 4. Treatment
interruptions were most commonly due to self-reported missed
doses for reasons unrelated to toxicity and did not differ
significantly between the groups. TB treatment was interrupted
in 13 (8.6%) children in the super-boosted group, three (6.5%) in
the double-dose, and two (2.6%) in the Ritonavir group. Two
children interrupted TB treatment due to hepatotoxicity (one in
the RTV and one in the double-dose group). When comparing
ALT levels measured 12 months after time0 there were no
differences between the groups.
Virologic, clinical and immunological response
The proportions of children who achieved viral load ,400 cop-
ies/ml by 6 months in the super-boosted LPV/r group (69.2%) did
not differ significantly from the comparison group (74.8%;
p=0.36). Children in the double-dose and ritonavir groups were
significantly less likely to be virally suppressed at 6 months (53.1%
and 49.3%) than comparisons (74.8% and 82.1%; p=0.02 and
p,0.0001, respectively). At 12 months after time0, only children
in the ritonavir group still had lower rates of virological
suppression relative to comparisons (Table 4). After adjusting for
pre-treatment CD4 percent and HAZ, the reduction in viral
suppression at 6 months associated with double-dose LPV/r was
attenuated and no longer significant (OR=0.703; 95% CI: 0.251–
1.966) but the association with ritonavir remained after adjusting
Table 2. Pre-antiretroviral treatment (ART) characteristics stratified by the modification made to the ART regimen among 294
children treated for TB and 232 comparison children not treated for TB at each site.
Super-Boosted
LPV/r (n=156)
Double dose
LPV/r (n=47)
Comparisons
Shezi (n=128) Ritonavir (n=91)
Comparisons
Neverest (n=104)
Sex
a
Male 72 (46.8) 28 (59.6) 54 (42.2) 53 (58.2) 55 (52.9)
Female 82 (53.2) 19 (40.4)
c 73 (57.5) 38 (41.8) 49 (47.1)
Age at ART start
Median (IQR) age in
months
12.99
(9.34–16.82)
b
13.22
(9.54–17.04)
14.82
(9.69–19.42)
11.25
(8.45–15.66)
11.43
(7.96–16.46)
,12 mos (%) 70(44.9) 21(44.7) 50(39.1) 48(52.8) 57(54.8)
12-,18 mos (%) 51(32.7) 17(36.2) 34(26.6) 29(31.9) 29(27.9)
18–24 mos (%) 35(22.4) 9(19.2) 44(34.4) 14(15.4) 18(17.3)
CD4 count in cells/ml
Median (IQR)
509
(221–847)
b
364
(165–740)
c
786
(456–1197)
661
(271–1079)
d
927
(636–1311)
CD4 percent
Median (IQR)
10.7
(7.1–16.8)
b
9.51
(4.96–16.7)
c
13.8
(10.5–18.6)
13.8
(9.26–18.5)
d
18.7
(13.6–23)
CD4 percent
,15% 106 (69.3) 32 (71.1) 72 (58.1) 51 (61.5) 30 (30.6)
15-,25% 32 (20.9) 12 (26.7) 33 (26.6) 22 (26.5) 49 (50)
$25% 15 (9.8) 1 (2.2) 19 (15.3) 10 (12.1)
d 19 (19.4)
Total 153 45 124 83 98
HIV RNA in copies/ml (%)
,100,000 24 (17.1) 5 (11.4) 27 (22.3) 8 (9.4) 11 (11.6)
100,000–749,999 55 (39.3) 15 (34.1) 45 (37.2) 26 (30.6) 29 (30.5)
$750,000 61 (43.6) 24 (54.6) 49 (40.5) 51 (60) 55 (57.9)
Total 140 44 121 85 95
Mean (SD) WAZ-score 23.28 (1.73)
b 23.11 (1.93)
c 22.34 (1.70) 22.70 (1.66)
d 22.07 (1.68)
Mean (SD) HAZ-score 23.27 (1.60)
b 23.17 (2.14)
c 22.62 (1.53) 23.64 (1.56)
d 23.14 (1.66)
aDenominators in each group are as shown.
bsuperboosted LPV/r group significantly different from Shezi comparisons p,0.05.
cdouble dose LPV/r group significantly different from Shezi comparisons p,0.05.
dritonavir group significantly different from Neverest comparisons p,0.05.
doi:10.1371/journal.pone.0017273.t002
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0.527). During follow-up fourteen children (4.8%) had one
additional modification to their ART regimen due to referral to
clinical sites with different policies. These children were classified
based on the regimen they received for the longest duration.
Excluding these children from the analysis had no impact on any
differences in responses observed between the groups.
CD4 percentages in the first 6 months were significantly lower
in all TB co-treatment groups compared to comparisons but this
was due to lower pre-treatment values. Changes in CD4
percentage were similar regardless of group. The median increase
in CD4% during the first 6 months of ART was 8.6% [IQR: 3.2-
13.8] in the super- boosted group, 7.1% [IQR: 0.2-14.0] in the
double-dose, and 9.3% [IQR: 4.4-14.9] in the ritonavir group. In
the comparisons, the median CD4% increase was 9.2% [IQR:
5.4-13.2] and 9.3% [IQR: 3.5-13.8] (Table 4).
Overall WAZ increased from 22.7361.8 at time 0 to
21.3461.4 at 6 months and to 20.8361.2 at 12 months. WAZ
was lower in the super-boosted and double-dose groups relative to
their comparisons at 6 months (p=0.004 and p,0.0001) but there
was no significant difference between the ritonavir group and the
control group. At 12 months, the super-boosted group continued
to have lower WAZ than the comparison group (21.1661.2 vs.
20.7761.1, p=0.01). From 0–6 months and from 0–12 months
after time 0, the mean WAZ change was highest in the super-
boosted group (WAZ change 1.5861.3 vs. 1.1 961.0 in the
comparisons; p=0.005 and 2.1961.5 vs. 1.3461.2; p,0.0001,
while the change from 0–6 months was not significantly different
between the other two TB co-treatment groups and their
comparisons (Table 4).
Discussion
In high HIV prevalence areas where the burden of TB co-
infection is also large, it is important to understand treatment
responses of children to ART and rifampin-based co-treatment.
During the South African ART rollout program beginning in
April 2004, clinical practices for children co-treated with
rifampicin and PI changed from switching to ritonavir, to super-
boosting and double dosing LPV/r. This study provides data on
virological, clinical and toxicity outcomes in children under 2 years
who received one of three different modifications to their PI-based
regimen whilst being co-treated with rifampicin-based TB therapy
compared to comparison children not treated for TB.
Children who received a ritonavir-based regimen together with
TB treatment were less likely to be virally suppressed at 6 months
than those receiving super-boosted LPV/r and the comparison
groups. In this group, poor virological outcomes may be explained
by increased resistance mutations developing when ritonavir alone
is used as part of combination ART.[21] Significant reductions in
ritonavir levels have also been described when used with
rifampicin and this might also explain the subsequent treatment
failure seen in this group of children.[22] These findings confirm
our prior results that ritonavir used alone in combination ART is a
poor choice,[23] particularly in children co-treated with rifampi-
cin, and should be avoided.
Virological suppression was similar in the super-boosted group
and their comparisons. Our findings are consistent with a pediatric
pharmacokinetic study which demonstrated that adding extra
ritonavir to ‘super-boost’ LPV results in therapeutic drug levels of
LPV.[24] However, super-boosting LPV/r has practical barriers
and adds complexity to pediatric ART for the children, care-
providers and for those maintaining stock control, since ritonavir is
poorly palatable and has a short shelf-life. Clinicians, on occasion,
elected the simpler approach of doubling the LPV/r dose.
Pharmacokinetic studies have now suggested that this may result
in an inadequate dose of LPV when used with rifampicin.[11] Our
data showed that although viral suppression rates at six months
were lower in those who received double dose LPV/r compared to
super-boosted or comparisons, interestingly, by the 12 months
viral load assessment, both groups had similar viral suppression
rates to comparisons. Since this approach has many practical
Table 3. Toxicity outcomes during 12 months after initiation of TB co-treatment by modification made to the PI-containing
regimen.
Super-Boosted LPV/r Double dose LPV/r Ritonavir
In follow up at last assessment 118 (75.6) 34 (72.3) 74 (81.3)
Died within 12 months 17(10.9) 1(2.1) 11(12.1)
Highest ALT while co treated for TB
Grade 0 (,38 IU/ml) 11(25)
a 10(45.5) 37(66.1)
Grade 1 (38–75 IU/ml) 20(45.5) 7(31.8) 10(17.9)
Grade 2 (76–150 IU/ml) 6(13.6) 2(9.1) 4(7.1)
Grade 3 (151–300 IU/ml) 4(9.1) 2(9.1) 2(3.6)
Grade 4.300 IU/ml 3(6.8) 1(4.6) 3(5.4)
Lowest Hemoglobin while co-treated for TB
Grade 0 (.10 g/dl) 15(79.0)
a 7(63.6) 18(48.7)
Grade 1 (8.5–10.0 g/dl) 3(15.8) 3(27.3) 13(35.1)
Grade 2 (7.5–8.4 g/dl) 1(5.3) 1(9.1) 4(10.8)
Grade 3 (6.5–7.4 g/dl) 0(0) 0(0) 1(2.7)
Grade 4 (,6.5 g/dl) 0(0) 0(0) 1(2.7)
ART interrupted 6(3.9) 3(6.4) 8(8.8)
TB treatment interrupted 13(8.6) 3(6.5) 2(2.6)
aToxicity outcomes in children on superboosted LPV/r significantly different to children taking ritonavir only if $ grade 1 is selected as the cut-off.
doi:10.1371/journal.pone.0017273.t003
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possibly at higher or more frequent doses, is required.
Ritonavir and the antituberculous drugs, particularly rifampicin
and isoniazid have the potential to cause severe liver toxicity that
could potentiate each other. Adult studies have shown that
superboosting PI’s may result in excess toxicity[10] and the Center
for Disease Control and Prevention (CDC) cautions against TB co-
treatment with super-boosted PI’s.[25] In our cohort, there were
no significant differences in the proportions of children with grade
3/4 ALT elevations in the TB co-treatment groups whilst
receiving TB treatment compared to children on LPV/r alone.
There were also only few treatment interruptions due to toxicity.
This suggests that the use of boosted LPV/r and TB treatment in
this group was generally well tolerated. After completion of TB
therapy, there was no undue liver function derangement among
those who had previously been on co-treatment for TB and HIV.
Mortality rates were similar between the TB-treated and
comparison groups, despite the fact that the children who received
TB treatment were generally sicker and younger than the
comparisons. The non-significant differences within the TB-
treated groups is probably a chance occurrence due to small
numbers, since it is unlikely that the differences in treatment
modality would have had a protective effect. It is possible that
some children in the comparison groups had undiagnosed TB or
other opportunistic infections that increased their risk of death
after commencing ART.
Currently there is no good alternative to rifampin-containing
TB regimens for first-line TB treatment. A regimen without
rifampicin is likely to result in delayed sputum conversion,
prolonged duration of therapy and a higher incidence of
relapse.[26,27] In this class of drugs rifampicin is the only
available option for the treatment of children. Rifabutin, which
has been recommended for use with PI-containing regimens for
adults [25] has been unavailable in resource-poor settings and
there is no suitable rifabutin dosing and formulation for children.
There are limited ART options for infants who also have TB.
Efavirenz is recommended for older children who require TB
treatment and there does not appear to be significant interaction
with rifampicin.[28] Efavirenz dosing in children ,3 years of age
is yet to be determined. WHO recommends that NVP at maximal
Table 4. Virologic, clinical and immunological outcomes at 6 and 12 months between children co-treated for TB stratified by the
modifications made to their PI-based regimen and comparisons not co-treated for TB.
Super-Boosted
LPV/r
Double dose
LPV/r
Comparisons
Shezi Ritonavir
Comparisons
Neverest
6 months after time 0
N 120 32 103 75 84
Median (IQR) CD4 count 1265 (880–1712) 1084 (54–1609)
b 1375 (1025–1797) 1370 (1007–2166)
c 1723 (1258–2485)
Median (IQR) CD4% 20.8 (15.9–27.4)
a 19.5 (12.7–26.6)
b 24.7 (18.9–30.5) 23.9 (16.6–30.0)
c 29.1 (20.0–33.2)
CD4%,15 26(21.7) 12(37.5) 14(14.4) 14(20) 5(6.2)
CD4% 15–24.9 57(47.5) 8(25.0) 36(37.1) 26(37.1) 28(34.6)
CD4%$25 37(30.8)
a 12(37.5)
b 47(48.5) 30(42.9)
c 48(59.3)
Median CD4% change (IQR) 8.60 (3.2–13.80) 7.08 (0.2–14.0) 9.17 (5.39–13.19) 9.30 (4.40–14.9) 9.3 (3.5–13.8)
VL,400 c/ml 81(69.2) 17(53.1) 77(74.8) 37(49.3) 69(82.1)
VL$400 c/ml 36(30.8) 15(46.9)
b 26(25.2) 38(50.7)
c 15(17.9)
Mean (SD) WAZ -score 21.75(1.34)
a 21.93(1.79)
b 21.00(1.24) 21.26(1.56) 20.94(1.24)
Mean WAZ change 1.58(1.25)
a 1.28(1.40) 1.19(1.00) 1.44(1.11) 1.11(1.14)
Mean (SD) HAZ score 22.93(1.36) 23.11(1.79) 22.59(1.31) 23.71(1.57) 23.27(1.58)
Mean HAZ score change 0.53(1.24)
a 0.48(1.75) 20.016(1.28) 0.043(1.68) 20.24(1.44)
12 months after time0
N 106 27 84 61 36
Median (IQR) CD4% 26.0 (20.1–33.2) 25.0(15.2–33.1) 26.6 (21.8–32.3) 27.4(21.0–32.5)
c 30.8(27.3–33.5)
CD4%,15% 15(13.0) 6(20.7) 5(5.4) 3(5.4) 0(0)
CD4% 15-,25% 32(30.2) 7(25.9) 31(37.4) 21(38.2) 3(10.7)
CD4%$25% 59(55.7) 14(51.9)
b 47(56.6) 31(56.4)
c 25(89.3)
Median CD4% change 13.6(4.8–19.6) 11.8 (7.2–19.4) 11.5(7.2–17.9) 13.9(8.4–20.6) 13.3(7.1–19.4)
VL,400 c/ml 87(82.9) 20(76.9) 70(83.3) 39(63.9) 30(83.3)
VL$400 c/ml 18(17.1) 6(23.1) 14(16.7) 22(36.1)
c 6(16.7)
Mean (SD) WAZ-score 21.16(1.24)
a 21.06(1.35) 20.77(1.08) 20.57(1.33) 20.37(1.04)
mean WAZ change 2.19(1.53)
a 2.06(1.77) 1.34(1.21) 2.08(1.27)
c 1.34(1.45)
Mean (SD) HAZ-score 22.69(1.36)
a 22.60(1.73) 22.32(1.11) 23.21(1.44) 23.04(1.38)
mean HAZ score change 0.81(1.48)
a 0.98(1.89) 0.31(1.20) 0.43(1.64) 0.08(1.88)
asuper-boosted LPV/r group significantly different from comparisons p,0.05,
bdouble dose LPV/r group significantly different from comparisons p,0.05.
critonavir group significantly different from Neverest comparisons.
doi:10.1371/journal.pone.0017273.t004
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age when TB treatment is required.[29] Despite reassurance from
a trial that triple NRTI regimens have clinical benefit in
adults,[30] there was poorer potency in terms of virological and
immunlogical outcomes.[31] This option may therefore not be
ideal for infants in whom the viral load is usually very high. There
have been reports of adequate treatment responses with no excess
toxicity when nevirapine-containing regimens have been used
together with TB treatment,[30,32] although rifampicin enhances
nevirapine metabolism, leading to a risk of subtherapeutic
concentration.[33] Additionally, concerns about emergence of
nevirapine resistance following nevirapine prophylaxis have
resulted in revision of WHO guidelines which now recommend
PI-based therapy for infants starting ART who have failed
nevirapine-containing prophylaxis.[14] Results from a multi-
center trial confirm that, in the face of prior nevirapine exposure,
LPV/r is superior for treatment of infants.[34]
Despite concerns about excess toxicity in adults, in infants and
young children requiring ART and TB treatment who were
assessed for liver function during the course of co-treatment,
boosted LPV/r appears a safe and efficacious option for therapy.
Increasing the dose of LPV/r with TB treatment, appears a safe
alternative worth further exploration, albeit at higher or more
frequent doses. Modeling has demonstrated that increasing LPV/r
dosing by 2.5–5 times if given 12 hourly or decreasing the interval
between doses to 8 hourly when used with rifampicin-containing
TB therapy may result in therapeutic levels of lopinavir.[35]
Ongoing pharmacovigilance is warranted since our retrospective
data have limitations. The quest for new ART and TB
formulations that are potent, easy to prescribe and tolerable when
used together must urgently be pursued.
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